• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Healy James

    6/12/26 4:34:10 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HEALY JAMES

    (Last)(First)(Middle)
    C/O BIOAGE LABS, INC.
    5885 HOLLIS STREET, SUITE 370

    (Street)
    EMERYVILLE CALIFORNIA 94608

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    BioAge Labs, Inc. [ BIOA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$15.4806/10/2026A22,000 (1)06/09/2036Common Stock22,000$022,000D
    Explanation of Responses:
    1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
    /s/ Dov A. Goldstein as attorney-in-fact06/12/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $BIOA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    5/27/2026$36.00Buy
    Roth Capital
    5/13/2026$40.00Buy
    BTIG Research
    3/27/2026$50.00Buy
    Needham
    2/25/2026$60.00Outperform
    Oppenheimer
    2/18/2026$62.00Hold → Buy
    Jefferies
    1/27/2026$73.00Overweight
    Piper Sandler
    12/5/2025$12.00Underweight → Equal-Weight
    Morgan Stanley
    10/22/2025$10.00Neutral → Buy
    Citigroup
    More analyst ratings

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

    Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels Topline data anticipated in the second half of 2026 EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinic

    6/16/26 8:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs to Present at Upcoming Investor Conferences

    EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–4, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, are scheduled to participate in a fireside chat on Thursday, June 4 at 3:45–4:15 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. • Gol

    5/22/26 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

    Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun

    5/20/26 9:50:00 AM ET
    $BIOA
    $FATE
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pande Vijay Satyanand

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    6/12/26 4:37:11 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hemrajani Rekha

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    6/12/26 4:35:46 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Healy James

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    6/12/26 4:34:10 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on BioAge Labs with a new price target

    Roth Capital initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $36.00

    5/27/26 9:00:20 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on BioAge Labs with a new price target

    BTIG Research initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $40.00

    5/13/26 8:08:15 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on BioAge Labs with a new price target

    Needham initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $50.00

    3/27/26 8:46:31 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

    4/A - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:11:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:10:37 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    10/3/24 7:19:49 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    SEC Filings

    View All

    BioAge Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - BioAge Labs, Inc. (0001709941) (Filer)

    6/12/26 8:00:16 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.

    SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

    5/15/26 1:18:32 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BioAge Labs, Inc. (0001709941) (Filer)

    5/8/26 9:10:20 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Financials

    Live finance-specific insights

    View All

    BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

    120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinical-stage biopharm

    4/21/26 7:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/12/24 4:15:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by BioAge Labs Inc.

    SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

    10/4/24 8:21:35 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care